Evidence map›Paper›PMID 30084103›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.

Jing Wang, Zhi-Yi Zhang, Sharon Lu, Dan Powers, Vikram Kansra, Xiaodong Wang

Open access · hybridAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Rolapitant Is a Reversible Inhibitor of CYP2D6.Drug metabolism and disposition: the biological fate of chemicals · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jing WangTESARO, Inc., 1000 Winter St. North, Ste. 3300, Waltham, MA, 02451, USA.
Zhi-Yi ZhangTESARO, Inc., 1000 Winter St. North, Ste. 3300, Waltham, MA, 02451, USA.
Sharon LuTESARO, Inc., 1000 Winter St. North, Ste. 3300, Waltham, MA, 02451, USA.
Dan PowersTESARO, Inc., 1000 Winter St. North, Ste. 3300, Waltham, MA, 02451, USA.
Vikram KansraTESARO, Inc., 1000 Winter St. North, Ste. 3300, Waltham, MA, 02451, USA.
Xiaodong WangTESARO, Inc., 1000 Winter St. North, Ste. 3300, Waltham, MA, 02451, USA. xddwang@gmail.com.
Tesaro (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRolapitant is a neurokinin-1 receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed chemotherapy-induced nausea and vomiting. We evaluated the effects of rolapitant oral on the pharmacokinetics of probe substrates for cytochrome P450 (CYP) 2D6 (dextromethorphan), 2C9 (tolbutamide), 2C19 (omeprazole), 2B6 (efavirenz), and 2C8 (repaglinide) in healthy subjects.

methodsThis open-label, multipart, randomized, phase 1 study assessed cohorts of 20-26 healthy subjects administered dextromethorphan, tolbutamide plus omeprazole, efavirenz, or repaglinide with and without single, oral doses of rolapitant. Maximum plasma analyte concentrations (C

resultsRolapitant significantly increased the systemic exposure of dextromethorphan in terms of C

conclusionsInhibition of dextromethorphan by a single oral dose of rolapitant 180 mg is clinically significant and can last at least 7 days. No clinically significant interaction was observed between rolapitant and substrates of CYP2C9, CYP2C19, CYP2B6, or CYP2C8. CYP2D6 substrate drugs with a narrow therapeutic index may require monitoring for adverse reactions if given concomitantly with rolapitant.

Indexed as

Administration, OralAdolescentAdultAlkynesAntiemeticsBenzoxazinesCarbamatesCyclopropanesCytochrome P-450 CYP2B6Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2C8Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6DextromethorphanDrug CombinationsDrug InteractionsAlkynesAntiemeticsBenzoxazinesCarbamatesCyclopropanesCYP2B6 protein, humanCYP2C8 protein, humanCYP2C9 protein, humanCytochrome P-450 CYP2B6Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2C8Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6DextromethorphanDrug CombinationsefavirenzMolecular ProbesNeurokinin-1 Receptor AntagonistsOmeprazolePiperidinesrepagliniderolapitantSpiro CompoundsTolbutamideAntiemeticsCytochrome P450Drug interactionsNeurokinin-1 receptor antagonistRolapitant

Identifiers

PMID30084103
PMCPMC6373243
OpenAlexW2887737104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.